Eikon Therapeutics
EIKN
52 hedge funds and large institutions have $251M invested in Eikon Therapeutics in 2026 Q1 according to their latest regulatory filings, with 52 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
47.06% more ownership
Funds ownership: 0% → 47.06% (+47%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$51.3M |
| 2 |
BlackRock
New York
|
+$44.4M |
| 3 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$26M |
| 4 |
MC
Merck & Co
Kenilworth,
New Jersey
|
+$22.3M |
| 5 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
+$17.6M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QT
51
Quantbot Technologies
New York
| $11.6K | +$14.7K | +1,098 | New |
|
52
Barclays
London,
United Kingdom
| $3.36K | +$4.25K | +318 | New |
|
EIKN Hedge Fund Activity: Q1 2026 in Review
52 of the 8,152 institutional investors tracked by Wall St. Rank reported a position in Eikon Therapeutics (EIKN) for Q1 2026, worth a combined $251M.
Buyers outnumbered sellers: 52 funds opened new EIKN positions and 0 closed out — a net gain of 52 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $51.3M.
- 52 institutional investors held Eikon Therapeutics (EIKN) as of Q1 2026, up from 0 in Q4 2025.
- Funds reported $251M of Eikon Therapeutics stock for Q1 2026.
- 52 funds opened new Eikon Therapeutics positions in Q1 2026 and 0 closed out, a net change of +52 holders.
- The largest Eikon Therapeutics buyer in Q1 2026 was Fidelity Investments, an estimated $51.3M added.
Based on aggregated 13F filings for Q1 2026.